ELV
Elevance Health, Inc.Evidence as of 2026-09-25The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on ELV
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
No company profile on file for ELV yet.
Moneyta sentiment
Where the published evidence leans after the desk debated it, not a rating or a recommendation.
−0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled. The rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.3 of a possible +2; was -0.3 before debate) · confidence high. Revenues for Q2 2026 (fiscal quarter ended 2026-07-10) were $ 50,474,000,000, essentially flat with Q1 2026 (fiscal quarter ended 2026-04-15) revenue of $ 50,181,000,000, while operating income fell from $ 2,086,000,000 in Q1 2026 to $ 1,763,800,000 in Q2 2026 and net income fell from $ 1,764,000,000 to $ 1,463,800,000. Diluted EPS declined from $ 8.00 to $ 6.71 across those quarters as weighted‑average diluted shares fell from 220,400,000 to 217,900,000 and reported common shares outstanding declined from 220,704,667 on 1 February 2026 to 216,869,290 on 10 July 2026.
The filing record and valuation metrics add texture: the 2026 annual report flags PBM rebate‑remittance risk under the Consolidated Appropriations Act of 2026 and discloses roughly $ 39.5 billion of goodwill and intangibles (32.5% of assets) and a potential Blue Cross/Blue Shield re‑establishment assessment of about $ 3 billion based on a $ 98.33 fee per licensed enrollee. Trailing metrics show FCF ttm of $ 12,785,000,000, price/FCF ≈ 6.79, EV/EBITDA ≈ 13.36 on $ 8,020,000,000 EBITDA ttm, P/E ttm ≈ 14.35 on EPS ttm $ 27.75, and net debt roughly $ 20.8 billion.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else (no outside knowledge, no browsing), so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC (revenue, margins, income, debt and share count, quarter by quarter) and reports which way the trend is running.
Revenues for the fiscal quarter ended 30 June 2026 (fiscal Q2 2026, 2026-04-01 to 2026-06-30) were $50,474,000,000.
XBRL companyfacts · 0001156039-26-000060Revenues for the fiscal quarter ended 31 March 2026 (fiscal Q1 2026, 2026-01-01 to 2026-03-31) were $50,181,000,000.
XBRL companyfacts · 0001156039-26-000043Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full: its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet; its risk analysis fills in once that lands.
The 2026 annual report (filed 6 Feb 2026) adds disclosure that the Consolidated Appropriations Act of 2026 includes pharmacy benefit manager reforms requiring PBMs to remit all rebates, fees (other than bona fide service fees), and other remuneration received from entities such as manufacturers, which the company identifies as a risk to its pharmacy services business.
10-K filed 2026-02-06As of December 31, 2025 the company reported approximately $39.5 billion of goodwill and other intangible assets, representing 32.5% of total consolidated assets (disclosed in the 2026 annual report filed 6 Feb 2026).
10-K filed 2026-02-06Reads the signal panel above (momentum, volatility, drawdown, relative strength and beta) and ranks each against the whole research universe rather than judging it in isolation.
Six‑month momentum is +35.1% and ranks in the 88th percentile of the 563‑stock research universe as of 2026-09-24.
Moneyta signal set · 2026-09-24weakened in debateTwelve‑month momentum (12_1) is +28.7% and ranks in the 72th percentile of the 563‑stock research universe as of 2026-09-24.
Moneyta signal set · 2026-09-24weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
13F-reported institutional holders as of the period 2026-06-30 total $75.11B, with 1,620 holders and a quarter-over-quarter reported value change of 23.0%; the top five reported holders are BlackRock, Inc. ($7.34B), VANGUARD CAPITAL MANAGEMENT LLC ($5.44B), STATE STREET CORP ($4.03B), WELLINGTON MANAGEMENT GROUP LLP ($3.56B), and First Eagle Investment Management, LLC ($3.24B).
13F holdings · 1620 filers · as of 2026-06-30As of 2026-09-23T13:57:10.735542+00:00, the ETF VTI included the security with a weight of 0.18% of the fund.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Coverage on 10 September 2026 noted that Elevance used its Wells Fargo 21st Annual Healthcare Conference appearance to reinforce its earnings outlook and cost discipline, keeping valuation discussions active.
News · simplywall.st · 2026-09-21Several outlets published pieces framing recent price action and institutional flows in Elevance shares, including an article describing ELV movements as a liquidity pulse for institutional tactics on 21 September 2026.
News · news.stocktradersdaily.com · 2026-09-21Reads parsed Forms 3/4/5: who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Erin M. Wessling (EVP & Chief Legal Officer) reported a purchase of 255 shares on 2026-09-03 for a reported value of "$106k"; the filing lists action "code F" and does not indicate a trading plan.
Form 4 · Wessling Erin M (EVP & Chief Legal Officer) · $106k code F · 2026-09-03Ryan R. Craig (EVP & Chief HR Officer) reported a purchase of 144 shares on 2026-09-02 for a reported value of "$58k"; the filing lists action "code F" and does not indicate a trading plan.
Form 4 · Craig Ryan R (EVP & Chief HR Officer) · $58k code F · 2026-09-02Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model finds an implied free cash flow (FCF) growth rate of -15.18% (implied_growth = -0.1518) under the stated discount and terminal assumptions, meaning today’s price is consistent with a projected decline in FCF under those inputs.
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve‑month FCF is $12,785,000,000 (fcf_ttm = 12785000000.0), which is the cash‑flow base used by the implied‑growth calculation.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score. The argument is shown, not hidden, so you can judge the reasoning yourself.
Several contemporaneous items in the evidence jointly support a constructive reading of Elevance: sequential revenues were stable and slightly higher quarter-to-quarter while share counts and reported common shares outstanding fell meaningfully, consistent with active buybacks and share reduction that can boost per‑share cash flow metrics. Market signals show strong momentum and relative strength versus the S&P over 6–12 months, a golden‑cross technical posture, and recent analyst buy-side maintenance, which together indicate renewed investor interest and favorable market positioning. Valuation metrics — trailing FCF yield (price-to-FCF ~6.8) and P/E ~14.4 with TTM FCF and EBITDA bases reported — present empirically supported valuation anchors that some market participants interpret as attractive relative to cash-flow generation. Institutional ownership is large and increased quarter-over-quarter, and there are small insider purchases, adding corroborating on‑balance evidence of demand and engagement.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.38
39 surviving claims rest on 15 distinct sources; the heaviest analyst carries 20% of them, and 96% of what the desk raised survived the debate.
The evidence set rests on a moderate breadth of distinct sources but a relatively concentrated analyst influence and a very high survival rate from desk debate. That combination means the surviving read is fact‑dense and internally consistent, but still somewhat fragile to analyst or source bias — single analyst influence and few primary documents could shift conclusions if contradicted by new primary filings or material market moves.
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment. When the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here (no outside knowledge, no browsing), and each card shows who read it and what it contributed to the score.
12 filings· 3 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data, not retyped or estimated.
Read by Mercer+0.3 to the score
8 documents· 3 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes−1.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.1 to the score
3 holdings records· 2 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
2 filings
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state, with stated and inferred flags kept apart.
Read by Talbot+0.3 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only; it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal; the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
The full terminal on ELV Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Get this for the names you actually hold
Every name in your portfolio, researched the same way, plus the one thing no sample can show: how each one sits inside what you already own.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.